UPDATE 3-U.S. approves $2 mln Novartis gene therapy for rare, deadly muscle disorder
May 24, 2019 at 14:03 PM EDT
ZURICH/NEW YORK, May 24 - Swiss drugmaker Novartis won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.